Ofatumumab Lowers B-cell Counts and Helps Relapsing MS Patients Reach NEDA, Data Show
Ofatumumab (OMB157) elicits a strong and fast reduction in the levels of circulating immune cells in people with relapsing forms of multiple sclerosis (MS), effectively helping to stop disease activity, according to new data from the Phase 2 APLIOS trial. The medication was also found to be more…